-+ 0.00%
-+ 0.00%
-+ 0.00%

InflaRx Announces That It Intends To Develop Izicopan, An Oral C5A Receptor Inhibitor, In Life-Threatening Kidney Disorder AAV

Benzinga·05/06/2026 12:31:55
Listen to the news
  • InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases
  • Capital Markets Day highlighting the promise and potential of izicopan in AAV and broader renal disorders now planned for summer 2026
  • The Company estimates it will have sufficient funds for currently planned clinical development activities and ongoing operations through 2029
  • InflaRx will continue to engage in dialog with potential collaborators to advance its development goals with izicopan across all geographies